Updated Analysis Finds Newer Type of LDL-C Reducing Drugs Still Not Cost-effective
Medindia,
An updated analysis of the low-density lipoprotein cholesterol (LDL-C) lowering drugs, proprotein convertase subtilisin/kexin…
An updated analysis of the low-density lipoprotein cholesterol (LDL-C) lowering drugs, proprotein convertase subtilisin/kexin…
Die FOURIER-Studie hat die klinische Wirksamkeit des cholesterinsenkenden PCSK9-Inhibitors Evolocumab bestätigt (wie Medscape…
By Karen Pallarito HealthDay Reporter Latest Cholesterol News TUESDAY, Aug. 22, 2017 (HealthDay News) -- Are new medicines for…